<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Research - Ma Lab | UAB</title>
    <meta name="description" content="Cancer immunotherapy research focusing on DNA damage responses, POLE/POLD1 mutations, and checkpoint blockade mechanisms.">
    <link rel="stylesheet" href="styles.css">
</head>
<body>Pleas
    <nav class="navbar">
        <div class="nav-container">
            <div class="nav-logo">
                <h2><a href="index.html">Ma Lab</a></h2>
            </div>
            <ul class="nav-menu">
                <li><a href="index.html">Home</a></li>
                <li><a href="research.html" class="active">Research</a></li>
                <li><a href="people.html">People</a></li>
                <li><a href="publications.html">Publications</a></li>
                <li><a href="contact.html">Contact</a></li>
            </ul>
        </div>
    </nav>

    <main>
        <section class="section">
            <div class="container">
                <div class="research-overview">
                    <h2>Research Overview</h2>
                    <p>Ma Lab investigates the fundamental mechanisms of immune surveillance during cancer development and therapy. We focus on understanding how DNA damage responses, mutagenesis processes, and epigenetic disruptions shape tumor immunogenicity and influence treatment resistance, with the ultimate goal of developing novel cancer vaccines, TCR therapies, and combination treatments that maximize the potential of the immune system. </p>
                </div>

                <div class="research-areas">
                    <h2>Research Directions</h2>
                    <div class="research-grid">
                        <div class="research-card">
                            <div class="research-icon">üß¨</div>
                            <h3>DNA damage repair and tumor immunology</h3>
                            <p>Our previous research demonstrated that DNA damage repair deficiencies lead to accumulation of immunogenic mutations, fundamentally alter the tumor immune microenvironment, and enhance tumor sensitivity to immune checkpoint blockade therapy. However, the complex interplay between DNA damage response pathways and immune surveillance mechanisms in cancer requires deeper investigation to fully understand and therapeutically exploit. </p>
                            <div class="research-techniques">
                                <h4>Research Aims:</h4>
                                <ul>
                                    <li>Understanding how DNA damage repair deficient tumors developed primary and acquired resistance to immune checkpoint blockade therapies</li>
                                    <li>Characterizing DNA damage response in tumor-infiltrating immune cells and its impact on anti-tumor immunity.</li>
                                    <li>Exploring how biochemical features of neoantigen peptides determine the immunogenicity of the mutagenesis processes</li>
                                </ul>
                            </div>
                        </div>

                        <div class="research-card">
                            <div class="research-icon">üéØ</div>
                            <h3>Immunological vulnerability of epigenetic dysregulated tumors</h3>
                            <p>Epigenetic dysregulation is a hallmark of cancer progression and drug resistance development. This dysregulation can also drive aberrant expression of non-canonical tumor antigens, potentially creating immunological vulnerabilities that may be targeted for therapeutic benefit.</p>
                            <div class="research-techniques">
                                <h4>Key Techniques:</h4>
                                <ul>
                                    <li>Elicidating the landscape of non-canonical tumor antigens associated with diverse epigenetic dysregulation in tumors</li>
                                    <li>Developing cancer vaccine and TCR therapies to target epigenetic dysregulation </li>
                                </ul>
                            </div>
                        </div>

                        <div class="research-card">
                            <div class="research-icon">üî¨</div>
                            <h3>Neoantigen TCR Discovery Pipeline</h3>
                            <p>Establishing experimental and computational frameworks for neoantigen identification and T cell receptor discovery to enhance personalized immunotherapy approaches. We develop novel algorithms for predicting immunogenic neoantigens.</p>
                            <div class="research-techniques">
                                <h4>Key Techniques:</h4>
                                <ul>
                                    <li>Machine learning algorithms</li>
                                    <li>High-throughput sequencing</li>
                                    <li>Computational immunogenomics</li>
                                </ul>
                            </div>
                        </div>

                        <div class="research-card">
                            <div class="research-icon">‚öóÔ∏è</div>
                            <h3>POLE/POLD1 Functional Landscapes</h3>
                            <p>Characterizing how DNA polymerase epsilon and delta mutations create hypermutated tumors with enhanced immunogenicity and checkpoint blockade sensitivity. Published as senior author in Nature Genetics (2022).</p>
                            <div class="research-techniques">
                                <h4>Key Techniques:</h4>
                                <ul>
                                    <li>Multi-omics data integration</li>
                                    <li>Functional genomics</li>
                                    <li>Clinical outcome analysis</li>
                                </ul>
                            </div>
                        </div>

                        <div class="research-card">
                            <div class="research-icon">üíâ</div>
                            <h3>Hypoalbuminemia & Immunotherapy</h3>
                            <p>Investigating the metabolic and pharmacological consequences of low serum albumin and its impact on immune checkpoint blockade efficacy. Understanding how systemic factors affect immunotherapy outcomes.</p>
                            <div class="research-techniques">
                                <h4>Key Techniques:</h4>
                                <ul>
                                    <li>Clinical data mining</li>
                                    <li>Biomarker analysis</li>
                                    <li>Pharmacokinetic modeling</li>
                                </ul>
                            </div>
                        </div>

                        <div class="research-card">
                            <div class="research-icon">üìä</div>
                            <h3>Immunogenomic Analysis</h3>
                            <p>Performing large-scale immunogenomic analysis on patient cohorts to identify genomic factors associated with improved immunotherapy responsiveness. Developing predictive models for treatment outcomes.</p>
                            <div class="research-techniques">
                                <h4>Key Techniques:</h4>
                                <ul>
                                    <li>Big data analytics</li>
                                    <li>Machine learning</li>
                                    <li>Statistical modeling</li>
                                </ul>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="funding-section">
                    <h2>Current Funding</h2>
                    <div class="funding-item">
                        <h3>Developing novel T cell receptors agents to target the EGFR T790M resistance mutation</h3>
                        <p><strong>Principal Investigator:</strong> Xiaoxiao Ma<br>
                        <strong>Funding Agency:</strong> Cleveland Clinic Foundation<br>
                        <strong>Grant Number:</strong> CCG0179<br>
                        <strong>Period:</strong> 01/2023 - 12/2023<br>
                        <strong>Award Type:</strong> Caregiver Catalyst Grant</p>
                    </div>
                </div>

                <div class="collaborations-section">
                    <h2>Key Collaborations</h2>
                    <div class="collaborations-grid">
                        <div class="collaboration-item">
                            <h4>Timothy A. Chan, MD, PhD</h4>
                            <p>Former mentor at Cleveland Clinic and Memorial Sloan Kettering Cancer Center. Ongoing collaborations in immunotherapy and tumor immunology.</p>
                        </div>
                        <div class="collaboration-item">
                            <h4>UAB O'Neal Comprehensive Cancer Center</h4>
                            <p>Translational research collaborations with clinical teams for biomarker validation and patient cohort studies.</p>
                        </div>
                        <div class="collaboration-item">
                            <h4>Department of Genetics, UAB</h4>
                            <p>Interdisciplinary collaborations in genomics, bioinformatics, and computational biology.</p>
                        </div>
                    </div>
                </div>
            </div>
        </section>
    </main>

    <footer>
        <div class="container">
            <div class="footer-content">
                <div class="footer-info">
                    <h3>Ma Lab</h3>
                    <p>Department of Genetics<br>
                    University of Alabama at Birmingham<br>
                    Birmingham, AL</p>
                </div>
                <div class="footer-contact">
                    <h3>Contact</h3>
                    <p>Email: <a href="mailto:xma2@uab.edu">xma2@uab.edu</a><br>
                    Phone: 205-934-5948</p>
                </div>
            </div>
            <div class="footer-bottom">
                <p>&copy; 2025 Ma Lab, University of Alabama at Birmingham. All rights reserved.</p>
            </div>
        </div>
    </footer>

    <script src="script.js"></script>
</body>
</html>
